Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...

Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

Curevo Vaccine raises $110M Series B for shingles vaccine trial extension, adds Moncef Slaoui as board chair and Moderna's Tal Zaks to board. Aims to compete with GSK's Shingrix.

Dr. Slaoui has been serving on the Company’s Board of Directors since June 2024. “Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are ...

GlaxoSmithKline has fired its former research boss Moncef Slaoui from the board of Galvani Bioelectronics, a company it majority owns, after an internal investigation found he sexually harassed a ...

Moncef Slaoui has stepped down from positions at three more companies, shortly after being dismissed from a firm owned by GlaxoSmithKline for alleged sexual harassment. In the space of 24 hours ...

Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of directors since June 2024. Published first on TheFly ...

View Full Profile. Learn about our Editorial Policies. Moncef Slaoui, the former head of the US government’s COVID-19 vaccine initiative called Operation Warp Speed, has been fired from the Galvani ...